Diabetes, Metabolic Syndrome and Obesity (Oct 2020)

Anti-Diabetic Effect of Telmisartan Through its Partial PPARγ-Agonistic Activity

  • Ayza MA,
  • Zewdie KA,
  • Tesfaye BA,
  • Gebrekirstos ST,
  • Berhe DF

Journal volume & issue
Vol. Volume 13
pp. 3627 – 3635

Abstract

Read online

Muluken Altaye Ayza, Kaleab Alemayehu Zewdie, Bekalu Amare Tesfaye, Selamawit Tesfamariam Gebrekirstos, Derbew Fikadu Berhe Department of Pharmacology and Toxicology, School of Pharmacy, Mekelle University, Mekelle, EthiopiaCorrespondence: Muluken Altaye Ayza Tel +251-916707913 Email [email protected]: Telmisartan is an angiotensin II receptor antagonist, which selectively inhibits the angiotensin II type 1 receptor. Thus, it is widely used for hypertension management. Nowadays, telmisartan’s effect on peroxisome proliferator-activated receptors (PPARs) is gaining wider attention. PPARs are ligand-activated transcription factors that belong to the nuclear hormone receptor superfamily. Telmisartan is reported to have a partial PPARγ-agonistic effect while avoiding the safety concerns found with full PPARγ agonists (thiazolidinediones). Telmisartan could be an alternative treatment option, with dual benefit for diabetes mellitus (DM) and hypertension. This review summarizes the anti-diabetic activity of telmisartan via its partial PPARγ-agonistic activity.Keywords: diabetes mellitus, hypertension, peroxisome proliferator-activated receptors, telmisartan

Keywords